Erythropoietin or darbepoetin for patients with cancer
2,064 results
1 - 100
Erythropoietin or darbepoetin for patients with cancer- Erythropoietin or Darbepoetin for patients with cancer ‐ meta‐analysis based on individual patient data
Psychosocial support for patients with cancer - Testing for cancer in patients with unprovoked venous thromboembolism
- Aromatherapy and massage for symptom relief in patients with cancer
- Interventions for preventing oral mucositis for patients with cancer receiving treatment
- Interventions for preventing oral candidiasis for patients with cancer receiving treatment
- Strategies for detecting colon cancer in patients with inflammatory bowel disease
- Anterior versus posterior mediastinal reconstruction after esophagectomy for patients with esophageal cancer
- Duration of adjuvant chemotherapy for patients with non‐metastatic colorectal cancer
- Blood transfusions for anaemia in patients with advanced cancer: Cochrane systematic review
- Supportive care for patients with gastrointestinal cancer: Cochrane systematic review
- Duration of adjuvant chemotherapy for patients with non-metastatic colorectal cancer
- Combined chemo-endocrine adjuvant therapy for patients with operable breast cancer
- Psychosocial interventions for patients with head and neck cancer: Cochrane systematic review
- Routine versus selective antifungal administration for control of fungal infections in patients with cancer
- Oral anticoagulation for prolonging survival in patients with cancer
- En‐bloc resection versus conventional transurethral resection for patients with non‐muscle‐invasive bladder cancer
- Palliative radiotherapy regimens for patients with thoracic symptoms from non‐small cell lung cancer
- Anticoagulation for the intial treatment of venous thromboembolism in patients with cancer
- Surgery versus radiosurgery for patients with a solitary brain metastasis from non‐small cell lung cancer
Selenium not helpful for patients with bladder cancer; vitamin E may be harmful- Routine versus selective antifungal administration for control of fungal infections in patients with cancer
- Interventions for preventing oral mucositis in patients with cancer receiving treatment: oral cryotherapy
- Interventions for treating oral candidiasis for patients with cancer receiving treatment: Cochrane systematic review
- Empirical antibiotics targeting gram‐positive bacteria for the treatment of febrile neutropenic patients with cancer
- Anticoagulation for the long term treatment of venous thromboembolism in patients with cancer
- SR: limited data on acupuncture for control of hot flashes in patients with cancer
- Non‐invasive interventions for improving well‐being and quality of life in patients with lung cancer
- Anticoagulation for thrombosis prophylaxis in cancer patients with central venous catheters
- Interventions for treating oral mucositis for patients with cancer receiving treatment: Cochrane systematic review
- Second or third additional chemotherapy drug for non‐small cell lung cancer in patients with advanced disease
- Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease
- Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors
- Surgical sealant for preventing air leaks after pulmonary resections in patients with lung cancer: Cochrane systematic review
- Extended anticoagulation for patients with low-risk pulmonary embolism and cancer has marginal benefit (ON COPE)
- Corticosteroids for adult patients with advanced cancer who have nausea and vomiting (not related to chemotherapy, radiotherapy, or surgery)
- Chemotherapy for malignant germ cell ovarian cancer in adult patients with early stage, advanced and recurrent disease
- Diagnostic tests for oral cancer and potentially malignant disorders in patients presenting with clinically evident lesions
- Systemic treatments for the prevention of venous thrombo‐embolic events in paediatric cancer patients with tunnelled central venous catheters
- Expert panels: Continue opioids but increase monitoring for patients with cancer-related pain who also use nonmedical stimulants
- Erythropoietin or darbepoetin for patients with malignant disease
- Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced disease
- Non-resection versus resection for an asymptomatic primary tumour in patients with unresectable Stage IV colorectal cancer: Cochrane systematic review
- Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression‐free survival in patients with advanced and/or metastatic colorectal cancer
- PET‐CT for assessing mediastinal lymph node involvement in patients with suspected resectable non‐small cell lung cancer
- Intravenous iron versus oral iron versus no iron with or without erythropoiesis‐ stimulating agents (ESA) for cancer patients with anaemia: a systematic review and network meta‐analysis
- Methylphenidate, hematopoietic agents helpful in cancer-related fatigue
- Pharmacological treatments for fatigue associated with palliative care
- Anaemia of chronic disease (ACD)
- Erythropoiesis-stimulating agents increase risk of VTE/death in CA patients
- Darbepoetin alfa minimally effective, increases stroke risk in diabetic nephropathy
- Aggressive increase in Hgb does not improve QOL
- Erythropoietin as an adjuvant treatment with (chemo) radiation therapy for head and neck cancer
- Pre and peri‐operative erythropoeitin for reducing allogeneic blood transfusions in colorectal cancer surgery.